Concepedia

Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model

Asma Lamine, Myriam Létourneau, Ngoc Duc Doan, Julie Maucotel, Alain Couvineau, Hubert Vaudry, David Chatenet, David Vaudry, Alain Fournier

Neuropharmacology · 2015 · 50 citations · 42 references

DOI

Concepts

References

42

Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies

Fernanda Martins Lopes, Rafael Schröder, Mário Luiz Conte da Frota Júnior et al. · Brain Research · 2010 · 398 citations

, , +15

Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists

Steven P. Presgraves, Tariq Ahmed, Sabine Borwege et al. · Neurotoxicity Research · 2003 · 295 citations

, , +16

Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease

Augusta Pisanu, Daniela Lecca, Giovanna Mulas et al. · Neurobiology of Disease · 2014 · 275 citations · Full text

, , +17

MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.

J. William Langston, E. Langston, Ian Irwin · PubMed · 1984 · 254 citations

, , +17

Structural requirements for the occupancy of pituitary adenylate‐cyclase‐activating‐peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB‐OK‐1 cell membranes

Patrick Robberecht, Philippe Gourlet, Philippe De Neef et al. · European Journal of Biochemistry · 1992 · 220 citations · Full text

, , +16